A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 100, Issue 3, 2006, Pages 586-590

  Covens, Allan ^a   Blessing, John ^b   Bender, David ^c   Mannel, Robert ^d   Morgan, Mark ^e  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Primary peritoneal cancer; Recurrent platinum sensitive ovarian cancer; Tirapazamine

Indexed keywords

CISPLATIN; TIRAPAZAMINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG HYPERSENSITIVITY; EYE DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HEARING DISORDER; HUMAN; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CANCER; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISEASE; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TRIAZINES;

EID: 32844458030     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.032     Document Type: Article

References (27)

1. M. Markman, J. Markman, K. Webster, K. Zanotti, B. Kulp, and G. Peterson Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design J. Clin. Oncol. 22 2004 3120 3125
2. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 21 361(9375) 2003 2099 2106
3. 2 histography P.W. Vaupal D.K. Kelleher M. Gunderoth Tumor oxygenation 1995 Gustav Fischer Verlag Stuttgart 219 232
4. J.S. Bedford, and J.B. Mitchell The effect of hypoxia on the growth and radiation response of mammalian cells in culture Br. J. Radiol. 47 1974 687
5. C.J. Koch, J. Kruuv, and H.E. Frey The effect of hypoxia on the generation time of mammalian cells Radiat. Res. 53 1973 43
6. R.S. Bush, D.T. Jenkin, and W.E.C. Allt Definitive evidence for hypoxic cells influencing cure in cancer therapy Br. J. Cancer 37 Suppl III 1978 302
7. B.A. Teicher, S.A. Holden, and T.S. Al-A. Achi Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in FSaIIC murine fibrosarcoma Cancer Res. 50 1990 3339
8. R.K. Jain Delivery of novel therapeutic agents in tumours: physiological barriers and strategies J. Natl. Cancer Inst. 81 1989 570
9. E.M. Zeman, J.M. Brown, M.F. Lemmon, V.K. Hirst, and W.W. Lee SR4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells Int. J. Radiat. Oncol. Biol. Phys. 12 1986 1239
10. J.M. Brown SR4233 (Tirapazamine): a new anticancer drug exploitation hypoxia in solid tumours Br. J. Cancer 67 1993 1163
11. A.I. Minchinton, M.J. Lemmon, M. Tarcy, and D.J. Pollart Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo Int. J. Radiat. Oncol. Biol. Phys. 22 1992 701
12. E.M. Zeman, and J.M. Brown Pre- and post-irradiation radiosensitization by SR 4233 Int. J. Radiat. Oncol. Biol. Phys. 16 1989 967
13. M.A. Baker, E.M. Zeman, V.K. Hirst, and J.M. Brown Metabolism of SR-4233 by Chinese hamster ovary cells: basis of selective cytotoxicity Cancer Res. 48 1988 5947
14. K. Laderoute, P. Wardman, and A.M. Rauth Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide to a free radical Mol. Pharmacol. 40 1991 440
15. S. Senan, R. Rampling, M.A. Graham, P. Wilson, H. Robin Jr., and N. Eckardt Phase I and pharmacokinetic study of tirapazamin (SR 4233) administered every three weeks Clin. Cancer Res. 3 1997 31
16. M.J. Dorie, and J.M. Brown Tumor-specific, schedule dependent interaction of tirapazamine (SR 4233) and cisplatin Cancer Res. 53 1993 4633
17. S.A. Holden, B.A. Teicher, G. Ara, T.S. Herman, and C.N. Coleman Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma J. Natl. Cancer Inst. 84 1992 187
18. M.J. Dorie, and J.M. Brown Potentiation of the anticancer effect of cisplatin by the hypoxic cytotoxin tirapazamine P.W. Vaupal D.K. Kelleher M. Gunderoth Tumor oxygenation 1995 Gustav Fischer Verlag Stuttgart 125 135
19. M.J. Dorie, and J.M. Brown Modification of the antitumour activity of chemotherapeutic drugs by the hypoxic agent tirapazamine Cancer Chemother. Pharamacol. 39 1997 361
20. D.W. Siemann The in situ tumor response to combinations of cyclophosphamide and tirapazamine Br. J. Cancer 74 Suppl. 27 1996 S65
21. V.K. Langmuir, H.A. Rooker, M. Osen, H.L. Mendonca, and K.R. Laderoute Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts Cancer Res. 54 1994 2845
22. J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L.O. Elisson, and P. Clark Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors J. Clin. Oncol. 18 2000 1351 1359
23. C. Aghajanian, C. Brown, C. O'Flaherty, A. Fleischauer, J. Curtin, and R. Roemeling Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer Gynecol. Oncol. 67 1997 127 130
24. P.N. Lara Jr., P. Frankel, P.C. Mack, P.H. Gumerlock, I. Galvin, and C.L. Martel Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a California Cancer Consortium phase I and molecular correlative study Clin. Cancer Res. 9 2003 4356 4362
25. D.K. Armstrong, J.A. Blessing, K.Y. Look, R. Schilder, and E.R. Nunez A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study Invest. New Drugs 21 2003 373 377
26. S.C. Plaxe, J.A. Blessing, M.A. Bookman, and W.T. Creasman Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 84 2002 32 35
27. J. Treat, E. Johnson, C. Langer, C. Belani, B. Haynes, and R. Greenberg Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study Clin. Oncol. 16 1998 3524 3527